Savara Overview
- Founded
-
2007
- Status
-
Public
- Employees
-
35
- Stock Symbol
-
SVRA
- Investments
-
3
- Share Price
-
$2.64
- (As of Monday Closing)
Savara General Information
Description
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Contact Information
Website
www.savarapharma.com
Formerly Known As
Savara Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Drug Delivery
Stock Exchange
NAS
Primary Office
- 6836 Bee Cave Road, Building 3
- Suite 201
- Austin, TX 78746
- United States
+1 (512) 000-0000
Savara Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.64 | $2.75 | $1.02 - $2.82 | $304M | 114M | 175K | -$0.25 |
Savara Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 60,369 | (3,926) | (6,883) | 146,739 |
| Revenue | 0 | 0 | 257 | 0 |
| EBITDA | (37,631) | (40,365) | (47,440) | (77,093) |
| Net Income | (39,160) | (43,014) | (49,615) | (78,173) |
| Total Assets | 147,758 | 176,598 | 97,745 | 136,203 |
| Total Debt | 26,092 | 25,791 | 25,283 | 25,552 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Savara Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Savara Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Savara Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgr
Biotechnology
Austin, TX
35
As of 2022
00000
000000000
00000
000000
onsequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum
0000000000000
Westlake Village, CA
000
As of 0000
00000
000000 - 000
00000
0000 0
quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
0000 000000000
Austin, TX
00
As of 0000
000.00
0000000000 0
000.00
Add Comparison
Savara Competitors (22)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MannKind | Formerly VC-backed | Westlake Village, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 0000 000000000000 | Venture Capital-Backed | Austin, TX | 00 | 000.00 | 0000000000 0 | 000.00 |
| 0000000 | Formerly VC-backed | Stevenage, United Kingdom | 00 | 00000 | 000000&0 | 00000 |
| 0000000000 0000000 | Venture Capital-Backed | Brighton, United Kingdom | 00 | 0000 | 000000 - 000 | 0000 |
| 000000 000000 | Formerly VC-backed | Morristown, NJ | 0 | 00.000 | 000000 - 000 | 00.000 |
Savara Patents
Savara Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200115412-A1 | Separation of vancomycin and its degradation products | Inactive | 15-Oct-2018 | 0000000000 | |
| EP-3866829-A1 | Separation of vancomycin and its degradation products | Inactive | 15-Oct-2018 | 00000000 | |
| US-20140014107-A1 | Methods to administer formulations of aminoglycoside and fosfomycin combination for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis | Active | 12-Jul-2011 | 00000000000 | |
| US-8820323-B2 | Methods to administer formulations of aminoglycoside and fosfomycin combination for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis | Inactive | 12-Jul-2011 | 00000000000 | 00 |
| US-8826904-B2 | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis | Inactive | 12-Jul-2011 | A61K31/7036 | 00 |
Savara Executive Team (14)
Savara Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| An van Es-Johansson MD | Self | Board Member | 000 0000 |
| David Ramsay | Savara | Board Member | 000 0000 |
| Joseph McCracken | Self | Board Member | 000 0000 |
| Matthew Pauls JD | Self | Chairman & Chief Executive Officer | 000 0000 |
| Nevan Elam JD | Self | Board Member | 000 0000 |
Savara Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Savara Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Savara Investments & Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000 | 25-Jul-2018 | 000000000 | Buildings and Property | 000000 00 | |
| 0000 00000000 | 27-Apr-2017 | 0000000000 | 00000 | Pharmaceuticals | 000000 00 |
| Serendex Pharmaceuticals | 15-Jul-2016 | Merger/Acquisition | 000.00 | Buildings and Property | 000000 00 |
Savara Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 000000 | Pharmaceuticals | Austin, TX | 0000 |
Savara ESG
Risk Overview
Risk Rating
Updated May, 27, 2021
33.36 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 947
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 427
Rank
00.00
Percentile
